Morrison & Foerster advised Krystal Biotech on the deal. Krystal Biotech, Inc. announced its $200 million common stock offering at $75 per share. Goldman Sachs & Co....
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here